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Abstract

without oophorectomy protects against ovarian cancer. This population-based longitudinal
record-linkage study aimed to explore this relationship, overall and by age at hysterectomy,
time period, surgery type, and indication for hysterectomy.
Methods: We followed the female adult Western Australian population (837,942 women)
across a 27-year period using linked electoral, hospital, births, deaths, and cancer records.
Surgery dates were determined from hospital records, and ovarian cancer diagnoses (n=1,640)
were ascertained from cancer registry records. We used Cox regression to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) for the association between hysterectomy and
ovarian cancer incidence.
Results: Hysterectomy without oophorectomy (n=78,594) was not associated with risk of
invasive ovarian cancer overall (HR = 0.98, 95% CI = 0.85-1.11), or with the most common
serous subtype (HR = 1.05, 95% CI = 0.89-1.23). Estimates did not vary statistically
significantly by age at procedure, time period or surgical approach. However, among women
with endometriosis (5.8%) or with fibroids (5.7%), hysterectomy was associated with
substantially decreased ovarian cancer risk, overall (HR = 0.17, 95% CI = 0.12-0.24 and HR =
0.27, 95% CI = 0.20-0.36, respectively) and across all subtypes.
Conclusions: Our results suggest that for most women, having a hysterectomy with ovarian
conservation is not likely to substantially alter their risk of developing ovarian cancer.
However, our results, if confirmed, suggest that ovarian cancer risk reduction could be
considered as a possible benefit of hysterectomy when making decisions about surgical
management of endometriosis or fibroids.
Keywords: ovarian cancer, hysterectomy, record-linkage, endometriosis, fibroids
3
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Background: Recent studies have called into question the long-held belief that hysterectomy

Introduction

ovarian cancer, supported by a considerable body of older research (summarized in (1-3)).
However, many studies including women diagnosed more recently have not seen a protective
association; indeed, some reported modest increases in risk, as seen in a recent meta-analysis
(4) and subsequent studies (5, 6). This apparent shift could arise from changing surgical
practices or patient characteristics, changes in menopausal hormone therapy (MHT) use, or
perhaps improved reporting of oophorectomy status.
Hysterectomy is one of the most common major surgeries among women globally (7, 8);
understanding the true relationship between hysterectomy alone and ovarian cancer risk is
important to inform the current debate over the relative advantages of prophylactically
removing ovaries at hysterectomy. Our aim was to explore the association between
hysterectomy for benign indications and ovarian cancer risk, overall and by time period, age
at surgery, hysterectomy type, and indication for hysterectomy. We examined this question
using 45 years of administrative data from the Western Australian Data Linkage System
(WADLS) (9).

Methods
Study population and linkage
We conducted a retrospective cohort study including all women on the Western
Australian (WA) Electoral Roll (enrollment to vote is compulsory) when electronic records
began in 1988, or who registered subsequently. We restricted the cohort to women aged ≤45
years in 1975, when hysterectomy began to be reliably recorded, to minimize inclusion of
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Hysterectomy without oophorectomy has been traditionally considered protective against

women who had hysterectomies, oophorectomies, or cancer diagnoses before observation.

enrollment age within our observation period) were therefore eligible for the analysis. This
cohort was linked with the WA Hospital Morbidity Data Collection (HMDC; 1970-2014),
WA Cancer Registry (1982-2015), Midwives Notifications System (MNS; 1980-2013), and
WA Births (1950-1979) and Deaths (1988-2015) Registers, allowing follow-up from 1988
until mid-2015. The Western Australian Data Linkage Branch linked the datasets using
probabilistic linkage matching on identifying and demographic fields and provided deidentified data to the researchers. We excluded women with: recorded ovarian cancer,
oophorectomy, or hysterectomy for malignancy before their first electoral record (n=9805);
or data inconsistencies (implausible birthdates, births after hysterectomy, first electoral record
after death, or male-specific codes: n=1313).
The study received approval from QIMR Berghofer and WA Health Human Research
Ethics Committees.
Variable measurement
Our main outcome was diagnosis of primary invasive epithelial cancer in the ovary
(International Classification of Diseases [ICD]-10 code C56), fallopian tube (C57.0) or
peritoneum (C48), recorded in the WA Cancer Registry, hereafter referred to collectively as
‘ovarian cancer’. Available data included date/basis of diagnosis, and tumor site, behavior,
grade, and morphology. Using morphology ICDO-3 codes we classified cancers as serous,
mucinous, endometrioid, clear cell, or other.
The HMDC contains information on all public and private WA hospital separations,
including admission/discharge month and year, diagnosis codes (principal, 21 additional),
and surgical procedure codes (principal, 10 additional) (see Supplementary Tables 1 and 2
5
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Women born from 1930 to 1998 (the last birth-year for which women would reach electoral

for codes). We used procedure codes to ascertain hysterectomies, oophorectomies, and tubal
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ligations, and diagnosis codes to identify hysterectomy indications and ovarian cancer
diagnoses before cancer registry records began.
Birth-year (from electoral records) was provided in 5-year bands to protect anonymity;
we derived age by assigning birthdate as the lowermost end. Electoral records include
postcode, from which we derived remoteness of residence (major cities/inner regional/outer
regional/remote/very remote) using the Accessibility and Remoteness Index of Australia
(ARIA+) (10, 11), and socio-economic disadvantage quintiles using the Socio-Economic
Indexes for Areas (SEIFA) (12), at study entry. We determined parity using the Births
Register and MNS, assuming nulliparity at 1950 for women (n=68,218) who reached
reproductive age before records began.
Statistical analysis
We calculated person-time for each woman as the interval between study entry (her first
appearance in the available electoral records) and exit, determined as the earliest of: ovarian
cancer diagnosis; hysterectomy or unilateral/bilateral oophorectomy if followed within 6
months by ovarian cancer diagnosis (surgery date was then assigned as diagnosis date, as we
considered these surgeries were likely related to their cancer); or a censoring condition, at
which follow-up ceased. Censoring conditions were: all other unilateral/bilateral
oophorectomies (including at hysterectomy); hysterectomy for other malignancies
(predominantly endometrial); diagnosis of non-epithelial ovarian cancer; death; emigration;
or end of observation (30/06/2015). We calculated exposed and unexposed person-time
considering hysterectomy, parity, and tubal ligation as time-varying using the counting
process method (13). Thus person-time from entry until hysterectomy (or until exit, for

6

unexposed women) was considered unexposed; any observed time after hysterectomy (from

We performed Cox proportional-hazards regression, estimating hazard ratios (HRs) and
95% confidence intervals (CI) for the association between hysterectomy and ovarian cancer
incidence, overall and for different histologic subtypes, using age as the underlying time scale
(14). We stratified models by birth decade, and adjusted for age at entry, parity (≥3 vs 0-2
births), and tubal ligation (yes/no). We omitted SEIFA and ARIA from final models because
they did not change HRs for the main association. The proportional hazards assumption was
confirmed graphically by plotting Schoenfeld residuals against time.
We conducted additional analyses comparing risk associated with hysterectomy
performed in three eras (<1990, 1990-2002, >2002). Time periods were chosen based on
trends in MHT use, which may influence the association (15). MHT use decreased in the
1970s then increased again (1980s), became widespread during the 1990s, then declined
sharply from 2002 (16), when Women's Health Initiative investigators reported that
combined MHT use was associated with adverse health outcomes (17). We examined
whether the association varied by age (as a proxy for menopausal status) at hysterectomy,
considering <45 (mostly premenopausal women), 45-54 (peri-menopausal women), and ≥55
years (mostly post-menopausal women). We compared risk associated with abdominal or
vaginal hysterectomy (numbers were insufficient to examine solely laparoscopic
hysterectomy). Lastly, we performed analyses considering hysterectomy indication, focusing
on three common indications (endometriosis, uterine leiomyoma [fibroids], and genital
prolapse).
We conducted sensitivity analyses, including: varying elements of the methods (using
years as the time-scale); varying the population (to women <45 years when hospital [1970] or

7
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study entry, for women with prior hysterectomies) was considered exposed.

cancer registry [1982] records began, vs. applying no age restriction; excluding women

WA]; examining associations by birth cohort); selecting different comparison groups
(estimating associations for later vs. earlier hysterectomies in age/period analyses); and
restricting the outcome to cancer of the ovary (censoring at fallopian tube/peritoneal cancer
diagnosis).
Analyses were performed in SAS 9.4 (SAS Institute Inc., N.C.). Tests of statistical
significance were two-sided and we used an alpha level of 5% to determine statistical
significance; to determine the statistical significance of the hazard ratios in our analysis, we
assessed whether the 95% CI crossed 1.00.

Results
We included 837,942 women (aged 17-82 [median 30] years at entry, 17-87 [median 50]
at exit) contributing 15,738,607 person-years of follow-up. The cohort included 223,049
women (26.6%) who entered in 1988 (median age at entry/exit 38/65) and 614,893 women
(73.4%) who entered later (median age at entry/exit 26/45). Overall 78,594 women had a
recorded hysterectomy for a benign indication before study exit (28,091 occurred before
entry) and contributed 1,335,989 exposed person-years. There were 81,927 tubal ligations
before exit. At their study entry, 715,329 (85.4%) of women had 0-2 children and 122,613
(14.6%) had 3 or more; by study exit, 610,857 (72.9%) had 0-2 children, and 227,085
(27.1%) had 3 or more. At entry, 622,446 (74.3%) lived in major cities, 147,874 (17.6%) in
inner/outer regional and 60,228 (7.2%) in remote/very remote areas; 31.3% were in the least
and 16.9% in the most disadvantaged SEIFA quintile. There were 48,870 (5.8%) women with
a diagnosis of endometriosis (most at hysterectomy), 47,407 (5.7%) with fibroids (15,037 had
8
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entering after 1988 after usual enrollment age [>25 years; therefore women migrating into

both conditions), and 55,752 (6.7%) with prolapse. During the study window 1,640 women

mucinous, 146 endometrioid, and 90 clear cell cancers). Table 1 presents population
characteristics by hysterectomy/exposure status.
Hysterectomy was not associated with decreased risk of invasive epithelial ovarian
cancer overall (HR 0.98, 95%CI 0.85-1.11), or for the most common serous subtype (HR
1.05, 95%CI 0.89-1.23), after adjusting for age, tubal ligation, and parity. Effect estimates
were in the protective direction for mucinous (HR 0.55, 95%CI 0.28-1.06), endometrioid (HR
0.69, 95%CI 0.41-1.18) and clear cell (HR 0.56, 95%CI 0.27-1.16) tumors, but were not
statistically significant (Table 2).
Analyses by time period (Figure 1A) showed no association with ovarian cancer overall
for hysterectomies performed <1990 (HR 0.93, 95%CI 0.79-1.10), and a slightly positive but
statistically nonsignificant association for hysterectomies performed 1990-2002 (HR 1.14,
95%CI 0.93-1.40). The association for hysterectomies performed >2002 was inverse (HR
0.60, 95%CI 0.34-1.06), although not statistically significant. The association did not vary
substantively by age at hysterectomy: <45 years, HR 0.94 (95%CI 0.77-1.15); 45-55 years,
HR 1.01 (95%CI 0.84-1.21); >55 years, HR 0.96 (95%CI 0.68-1.34) (Figure 1B). Results by
type of hysterectomy are presented in Supplementary Table 3. There were too few cancers
to conduct period, age, or surgical type analyses by histologic subtype.
Our two a priori approaches to assess whether the association varied by indication were:
first, to adjust the main models for the indication(s) for hysterectomy; and second, to examine
in a separate model the association between hysterectomy for each indication coded at
surgery (a single multi-level variable) and risk, compared to no hysterectomy. Implementing
the first approach, we observed that after adjusting models for ever-diagnosis of
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were diagnosed with invasive epithelial ovarian cancer (including 1020 serous, 125

endometriosis or fibroids, estimates of the association decreased for ovarian cancer overall

mucinous HR 0.38, 95%CI 0.19-0.75; endometrioid HR 0.30, 95%CI 0.17-0.52; clear cell
HR 0.19, 95%CI 0.09-0.41) (Table 2). Further adjustment for prolapse did not substantially
alter effect estimates.
Implementing our second approach, we constructed a model estimating risk associated
with hysterectomy performed for each indication. We observed that, compared to women
without hysterectomy (which includes women with/without diagnosis of each indication),
estimates were in the direction of slightly increased ovarian cancer risk for hysterectomy for
endometriosis (without fibroids/prolapse) (HR 1.18, 95%CI 0.71-1.96), or fibroids (without
endometriosis/prolapse) (HR 1.10, 95%CI 0.79-1.55), and apparent slight decreased ovarian
cancer risk for hysterectomy for prolapse (without endometriosis/fibroids) (HR 0.89, 95%CI
0.67-1.18), although none were statistically significant (Table 3). However, these conditions
were associated with ovarian cancer risk irrespective of hysterectomy. Ever-diagnosis of
endometriosis was associated with increased ovarian cancer risk (HR 2.74, 95%CI 2.323.22), with particularly strong associations for endometrioid (HR 7.42, 95%CI 4.80-11.48)
and clear cell (HR 12.24, 95%CI 7.23-20.73) cancers (Supplementary Table 4). Everdiagnosis of fibroids was associated with increased risk overall (HR 1.97, 95%CI 1.69-2.30),
with little variation by subtype (Supplementary Table 4). Ever-diagnosis of prolapse was
associated with decreased risk overall (HR 0.68, 95%CI 0.57-0.80), with little variation by
subtype except a stronger inverse association for clear cell cancers (HR 0.38, 95%CI 0.160.89) (Supplementary Table 4).
To distinguish the effect of hysterectomy for a particular indication from the effect of the
condition itself, we implemented a third approach, stratifying by each condition and repeating
our analysis within those strata. We observed that among women ever diagnosed with
10
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(HR 0.65, 95%CI 0.56-0.75), and for each subtype (serous HR 0.76 [95%CI 0.63-0.91],

endometriosis, hysterectomy was associated with substantially decreased ovarian cancer risk

(Supplementary Table 5). Similarly, hysterectomy was associated with decreased risk
among women with fibroids (HR 0.27, 95%CI 0.20-0.36 overall) (Table 4), which again was
similar across subtypes (Supplementary Table 5). The strong inverse relationship among
women with endometriosis or fibroids remained, although was slightly attenuated, after
excluding women with the other condition (data not shown). Among women without
endometriosis, without fibroids, and with neither condition, there was no protective effect of
hysterectomy (for example, HR 1.15, 95%CI 0.98-1.35, overall, among women with neither
condition) (Table 4). In women with prolapse, the effect estimate was slightly elevated but
not statistically significant (HR 1.24, 95%CI 0.91-1.69) (Table 4).
Our results were robust to the method used to estimate person-years. Including older
women (relaxing/removing the age restriction) yielded similar estimates although some
became slightly inverse (Supplementary Table 6), consistent with the hypothesis that
including older women increases misclassification of women with prior oophorectomy.
Restricting analyses to younger women (<45 in 1982), or excluding women migrating into
WA, made little difference to estimates (Supplementary Table 6). There were no obvious
patterns by birth cohort, although numbers were generally too low to draw clear conclusions.
Estimates were similar when we repeated analyses defining outcome strictly as cancer of the
ovary (ICD code C56), except for a stronger inverse association for mucinous cancers (data
not shown).
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(HR 0.17, 95%CI 0.12-0.24, overall) (Table 4), with fairly consistent HRs across subtypes

In this large retrospective study using linked administrative data we found that
hysterectomy was not associated with decreased ovarian cancer risk either overall or for the
most common and aggressive form (serous cancer), and that reductions in risk were not
observed in earlier time periods. There was a suggestion of decreased risk of non-serous
ovarian cancers which was not statistically significant. The association varied minimally by
age at surgery or type of hysterectomy. Among women with endometriosis or fibroids, two
common indications for this procedure, hysterectomy was associated with substantially
decreased ovarian cancer risk.
While older studies had suggested a protective effect of hysterectomy on ovarian cancer
(18, 19), almost all recent studies have not shown this (20, 21). Our results are consistent with
recent findings; we did not see inverse associations even for hysterectomies performed in the
1970s/1980s. The discrepancy between older and newer studies may arise from better selfreporting of oophorectomy. Many women with documented bilateral oophorectomy report
that their ovaries have not been removed (22). It may be that women in older studies, with
hysterectomies undertaken further back in time, were less likely to be aware that
oophorectomy had been simultaneously performed. Our study avoids this bias by ascertaining
oophorectomy using hospital records.
Fluctuations in MHT use may have also influenced associations over time. MHT is
prescribed more frequently to women with hysterectomy than those without, and is associated
with modestly increased ovarian cancer risk (23). Two large studies have reported that
hysterectomy is associated with slightly increased ovarian cancer risk among ever-users of
MHT, but decreased risk among never-users (24, 25). Without data on MHT use we could not
12
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Discussion

directly explore its influence, but the slight increased risk associated with hysterectomies in

consistent with this pattern. However, we had short follow-up and few hysterectomies and
cancer diagnoses after 2002.
Some previous studies have suggested that hysterectomy at younger ages particularly
(<45 or <50) may be associated with reduced ovarian cancer risk (4). However, we found
little variation in the association by surgery age.
We found some evidence that the association varies by histologic subtype, with no
association seen for serous cancers but a suggestion of inverse relationships with non-serous
tumors, particularly mucinous and clear cell. These results closely match subtype-specific
estimates from a recent pooled analysis of 21 cohorts (6). Some (5, 26-28), but not all (29,
30), large case-control studies have also reported risk reductions for non-serous tumors.
A novel finding of our study was that hysterectomy appeared to substantially reduce risk
among women with endometriosis or fibroids (both of which were associated with
considerably increased ovarian cancer risk in our population). Few studies have considered
indication for hysterectomy. One case-control study reported that adjustment for
endometriosis, fibroids, and ovarian cysts decreased the odds ratio for the
hysterectomy/ovarian cancer association (24), as we found. An analysis pooling four casecontrol studies (2098 cases) compared women with/without endometriosis and, consistent
with our results, reported that hysterectomy was associated with possible decreased ovarian
cancer risk among women with endometriosis (OR 0.69, 95%CI 0.38-1.24) but not without
(OR 1.02, 95%CI 0.86-1.23) (31). Use of self-reported endometriosis, consequently including
a broader disease spectrum with more misclassification, may explain their weaker
association, as self-reported endometriosis is associated with lower ovarian cancer risk than

13
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the 1990s, when MHT was common, and reduced risk thereafter, when MHT use fell, is

surgically confirmed endometriosis (32). Another study of women with endometriosis found

hysterectomy did not (33). It is possible that the protective effect we observed is primarily
due to simultaneous removal of lesions. Fibroids have rarely been assessed in relation to
ovarian cancer. One Danish record-linkage study reported that women with fibroids are at
increased risk of ovarian cancer (RR 1.36, 95%CI 1.16-1.60), particularly endometrioid
tumors (RR 1.57, 95%CI 1.05-2.34) (34), a similar although slightly weaker association than
we observed. We know of no studies examining the hysterectomy/ovarian cancer relationship
by the presence/absence of fibroids. Our findings among women with these conditions, while
intriguing and plausible, were obtained from post-hoc subgroup analyses and require
replication.
Notable strengths of our study include its large size, population-based design, long-term
follow-up, and measurement of exposure and outcome using medical records. Compulsory
electoral enrollment allowed us to include virtually all female WA residents. Ascertaining
hysterectomy/oophorectomy status using hospital data eliminates recall error, a concern in
many previous studies. Misclassification of hysterectomy status is likely to be minimal, since:
the HMDC records all surgeries in WA; residents infrequently receive care elsewhere due to
geographic isolation (35); we restricted the analysis to younger women at the start of hospital
records; and excluding women migrating into WA during observation did not change our
findings. Precise information on surgery date allowed accurate classification of exposed time.
Reporting diagnoses of malignant solid tumors to the cancer registry is mandatory, so most
ovarian cancers after 1982 should be captured.
Our study is not without limitations. We may not have captured exposures or outcomes
occurring prior to available hospital records. We mitigated this by restricting to women aged
≤45 years in 1975 (the start of reliable hysterectomy data). Residual misclassification
14

Downloaded from https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djz015/5308404 by QIMR Berghofer Medical Research Institute user on 12 February 2019

that removal of endometriotic lesions substantially reduced ovarian cancer risk, while

resulting from unrecorded early hysterectomies (perhaps chiefly among 6.7% of women

have reduced the difference between exposed and unexposed groups, attenuating any
association. However, restricting our analysis to younger women resulted in similar
estimates, suggesting that misclassification was minimal. Our study design limited access to
information on some possible confounding factors, which are not usually recorded in
administrative data sources. However, the confounders we were able to include had
negligible influence on our effect estimates, and confounders which were unrecorded would
be expected to have modest effects (for instance, oral-contraceptive use is not strongly related
to hysterectomy [for example, (36)]). For the same reason we could not directly assess the
effect of any changes in MHT use over time. We compared the association between timeperiods chosen to reflect different levels of MHT use, and observed suggestive differences.
MHT use is only moderately associated with ovarian cancer risk (23) but could account for a
portion of the difference. Future studies examining this association should incorporate MHT
use if possible.
In summary, we conducted a large, population-based record-linkage study using up to 45
years of data for women in Western Australia. Our results for women with endometriosis and
fibroids require replication, but suggest that hysterectomy may reduce ovarian cancer risk
among these women. However, women without these conditions should not be advised that
hysterectomy alone will reduce their ovarian cancer risk.
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Characteristic
Age at study entry, y
<30
30-<40
40-<50
50-<60
60-<70
≥70
Tubal ligation at end of observation
No
Yes
Parity at end of observation
0
1
2
≥3
Endometriosis ‡
No
Yes
Fibroids ‡
No
Yes
Prolapse ‡
No
Yes
Socio-economic disadvantage score
(SEIFA§) quintile at study entry ||
1 (most disadvantaged)
2
3
4
5 (least disadvantaged)

No hysterectomy
(N=733,832)
No. (%)

Hysterectomy contributing
exposed time* (N=78,594)
No. (%)

Hysterectomy contributing no
exposed time † (N=25,516)
No. (%)

385,380 (52.5)
159,300 (21.7)
107,808 (14.7)
66,378 (9.0)
12,870 (1.8)
2,096 (0.3)

12,054 (15.3)
23,759 (30.2)
26,584 (33.8)
14,794 (18.8)
1,331 (1.7)
72 (0.1)

5,428 (21.3)
7,840 (30.7)
8,159 (32.0)
3,690 (14.5)
373 (1.5)
26 (0.1)

672,377 (91.6)
61,455 (8.4)

62,509 (79.5)
16,085 (20.5)

20,677 (81.0)
4,839 (19.0)

342,192 (46.6)
62,582 (8.5)
142,476 (19.4)
186,582 (25.4)

21,170 (26.9)
6,272 (8.0)
19,240 (24.5)
31,912 (40.6)

8,481 (33.2)
2,176 (8.5)
6,268 (24.6)
8,591 (33.7)

713,013 (97.2)
20,819 (2.8)

59,725 (76.0)
18,869 (24.0)

16,334 (64.0)
9,182 (36.0)

721,137 (98.3)
12,695 (1.7)

54,977 (70.0)
23,617 (30.0)

14,421 (56.5)
11,095 (43.5)

715,643 (97.5)
18,189 (2.5)

46,408 (59.0)
32,186 (41.0)

20,139 (78.9)
5,377 (21.1)

122,758 (16.7)
160,028 (21.8)
98,783 (13.5)
118,065 (16.1)
232,575 (31.7)

14,213 (18.1)
21,514 (27.4)
9,912 (12.6)
10,863 (13.8)
21,847 (27.8)

4,590 (18.0)
6,364 (24.9)
3,202 (12.5)
3,577 (14.0)
7,722 (30.3)
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Table 1: Demographic and reproductive characteristics of included women, by final hysterectomy status recorded 1970-2015

† These women had a hysterectomy but contribute only unexposed time to the analysis as their hysterectomy occurred at, or after, their study exit (these
women predominantly exited due to a bilateral/unilateral oophorectomy performed prior to, or at the time of, their hysterectomy), or was performed for a
non-benign indication (n=4632; at which time follow-up was censored if the woman had not already exited the study).
‡ Condition included as a diagnosis during any hospitalisations 1970-2015.
§ Socio-Economic Indexes for Areas.
|| Percentages do not add to 100% due to a small proportion of missing data.
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Remoteness at study entry ||
Major cities
548,088 (74.7)
55,110 (70.1)
19,248 (75.4)
Inner regional
63,417 (8.6)
7,880 (10.0)
2,108 (8.3)
Outer regional
63,584 (8.7)
8,811 (11.2)
2,074 (8.1)
Remote
36,015 (4.9)
4,295 (5.5)
1,212 (4.7)
Very remote
16,772 (2.3)
1,423 (1.8)
511 (2.0)
* These women had a hysterectomy for benign indications before their study exit (their hysterectomies occurred either before their first electoral record, or
during the study window) and therefore contribute exposed time to the analysis. Women whose hysterectomy was performed during the study window
contribute both unexposed and exposed time.

Adjustment models†
Adjustment 1
No hysterectomy
Hysterectomy‡
Adjustment 2
No hysterectomy
Hysterectomy‡

All invasive ovarian cancer
HR (95% CI)

Serous
HR (95% CI)

Mucinous
HR (95% CI)

Endometrioid
HR (95% CI)

Clear cell
HR (95% CI)

1.00 (Reference)
0.98 (0.85 to 1.11)

1.00 (Reference)
1.05 (0.89 to 1.23)

1.00 (Reference)
0.55 (0.28 to 1.06)

1.00 (Reference)
0.69 (0.41 to 1.18)

1.00 (Reference)
0.56 (0.27 to 1.16)

1.00 (Reference)
0.65 (0.56 to 0.75)

1.00 (Reference)
0.76 (0.63 to 0.91)

1.00 (Reference)
0.38 (0.19 to 0.75)

1.00 (Reference)
0.30 (0.17 to 0.52)

1.00 (Reference)
0.19 (0.09 to 0.41)

*

Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian cancer includes primary ovarian, fallopian tube, and peritoneal
cancer. For each histologic subtype analysis, follow-up time is censored at diagnosis of other subtypes. HR = hazard ratio; CI = confidence interval.

†

Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation (yes/no), and parity (3 or more vs 0-2 births) (Adjustment 1), and
additionally endometriosis (yes/no) and fibroids (yes/no) (Adjustment 2). Adjusting for genital prolapse (a third common indication for hysterectomy) did not
affect the association between hysterectomy and ovarian cancer, so this was not included in presented models.

‡

As hysterectomy is time-varying, the analysis compares exposed time (‘hysterectomy’, contributed by women after their hysterectomy) vs unexposed time (‘no
hysterectomy’, contributed by women before their hysterectomy and by women who did not have a recorded hysterectomy). We assigned date of hysterectomy
as date of hospital discharge. For the vast majority (99.9%) of the women in this analysis, admission and discharge dates for hospitalisation for hysterectomy
were identical (78.9%) or only one month apart (21.0%), because recovery in hospital after hysterectomy is typically short and the provided HMDC data
included admission/discharge month and year (not day).
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Table 2: Association between hysterectomy for a benign indication and invasive epithelial ovarian cancer, by histologic subtype*

Table 3: Association between hysterectomy for a benign indication and invasive
epithelial ovarian cancer*, by indication

†

Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation
(yes/no), and parity (3 or more vs 0-2 births). HR = hazard ratio; CI = confidence interval.

‡

We created a single time-varying variable for hysterectomy by indication. We defined indication
using codes recorded in any of the diagnosis fields at the time of surgery, in order to capture the
pathological context of the surgery as completely as possible. Women who had a hysterectomy
before study exit contribute exposed time to one of the indication categories from their
hysterectomy onwards. For each of the following categories, other conditions, such as those coded
as uterine disorders or disorders of menstruation, may have been also noted in the hospital record.
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Recorded hysterectomy indication
HR (95% CI)†
No hysterectomy
1.00 (Reference)
Hysterectomy performed for: ‡
Endometriosis (not fibroids or prolapse)
1.18 (0.71 to 1.96)
Fibroids (not endometriosis or prolapse)
1.10 (0.79 to 1.55)
Prolapse (not endometriosis or fibroids)
0.89 (0.67 to 1.18)
Fibroids and endometriosis (not prolapse)
0.80 (0.43 to 1.50)
Prolapse and endometriosis (not fibroids)
0.71 (0.32 to 1.58)
Prolapse and fibroids (not endometriosis)
1.16 (0.70 to 1.93)
Prolapse, fibroids and endometriosis
0.77 (0.32 to 1.85)
Other indications
0.98 (0.82 to 1.18)
* Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian
cancer includes primary ovarian, fallopian tube, and peritoneal cancer.

Table 4: Association between hysterectomy for a benign indication and invasive
epithelial ovarian cancer*, by presence of endometriosis, fibroids, and prolapse†
HR (95% CI)‡
1.00 (Reference)
0.17 (0.12 to 0.24)
1.00 (Reference)
1.09 (0.95 to 1.26)
1.00 (Reference)
0.27 (0.20 to 0.36)
1.00 (Reference)
1.09 (0.94 to 1.27)
1.00 (Reference)
0.26 (0.21 to 0.33)
1.00 (Reference)
1.15 (0.98 to 1.35)
1.00 (Reference)
1.24 (0.91 to 1.69)
1.00 (Reference)
0.97 (0.83 to 1.15)

*

Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian
cancer includes primary ovarian, fallopian tube, and peritoneal cancer.

†

Strata (presence/absence of each condition) are defined by whether the condition was included
as a diagnosis during any hospitalisations 1970-2015.

‡

Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation
(yes/no), and parity (3 or more vs 0-2 births). HR = hazard ratio; CI = confidence interval.
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Hysterectomy by presence of benign
gynaecological conditions
Women with endometriosis
No hysterectomy
Hysterectomy
Women without endometriosis
No hysterectomy
Hysterectomy
Women with fibroids
No hysterectomy
Hysterectomy
Women without fibroids
No hysterectomy
Hysterectomy
Women with endometriosis or fibroids
No hysterectomy
Hysterectomy
Women without endometriosis or fibroids
No hysterectomy
Hysterectomy
Women with prolapse
No hysterectomy
Hysterectomy
Women without prolapse
No hysterectomy
Hysterectomy

Figure legend

epithelial ovarian cancer, by (A) period of hysterectomy and (B) age at hysterectomy,
compared to no hysterectomy. Time was censored at hysterectomy for malignancy.
Hysterectomy is time-varying. Ovarian cancer includes primary ovarian, fallopian tube, and
peritoneal cancer. Models were stratified by decade of birth and adjusted for age at study
entry, tubal ligation (yes/no), and parity (3 or more vs 0-2 births). In B, patterns were similar
if we assigned birthdate at the electoral birth-year band midpoint.
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Figure 1: Association between hysterectomy for a benign indication and invasive
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